Advanced prostate cancer treatment
- Он увидел светловолосую девушку, помогающую Дэвиду Беккеру найти стул и сесть.
- Беккер вздохнул.
The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary. Studies on prostatic cancer.
Advanced Prostate Cancer: Living Longer, Living Better
The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. Treatment strategies for advanced prostate cancer.
Actualities in the medical treatment of metastatic prostate cancer. Novelties in diagnostics and treatment of prostate cancer.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer GETUG-AFU 15 : a randomised, open-label, phase 3 trial.
Lancet Oncol. J Clin Oncol.
One of the treatment options for advanced prostate cancer is androgen deprivation therapy, which uses drugs to lower levels of the hormones that help prostate cancer cells grow. Current FDA-approved treatments of this type are injected or placed as small implants under the skin. Orgovyx is an orally administered treatment that works by blocking the pituitary gland from making hormones called luteinizing hormone and follicle-stimulating hormone, thereby reducing the amount of testosterone the testicles are able to make. The safety and efficacy of Orgovyx was evaluated in a randomized, open-label trial in men with advanced prostate cancer.
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer STAMPEDE : survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
- Я уверена, что они смогут сказать.
- И пойдет на все, лишь бы эта информация не вышла из стен Третьего узла.
Lancet ; — Eur Urol. Ann Oncol.
Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer. Abiraterone and increased survival in metastatic prostate cancer.
BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK
Abiraterone in metastatic prostate cancer without previous chemotherapy. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.
Advanced prostate cancer treatment for prostate cancer not previously treated with hormone therapy. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
Megjelenés éve: Kivonat: The inevitable progression of advanced prostate cancer to castration resistance, and ultimately to lethal metastatic disease, depends on primary or acquired resistance to conventional androgen-deprivation therapy ADT and accumulated resistance strategies to evade androgen receptor AR suppression. In prostate cancer cells, AR adaptations that arise in response to ADT are not singular, but diverse, and include gene amplification, mutation and even complete loss of receptor expression. Collectively, each of these AR adaptations contributes to a complex, heterogeneous, ADT-resistant tumor. Here, we examined prostate cancer cell lines that model common castration-resistant prostate cancer CRPC subtypes, each with different AR composition, and focused on novel regulators of tumor progression, the Bromodomain and ExtraTerminal BET family of proteins. BRD4, a co-regulator of gene transcription, controls migration and invasion through transcription of AHNAK, a large scaffolding protein linked to promotion of metastasis in a diverse set of cancers.
Prostate Cancer Prostatic Dis.
